Introduction
The clinical data infrastructure that supports most Phase 2 and Phase 3 programs was built around a well-understood operational model: a defined patient population, established endpoints with historical precedent, experienced site teams, and laboratory workflows that have been executed hundreds of times before. That model shapes the default assumptions embedded in most electronic data capture systems — what gets validated, what gets flagged, what gets left to site judgment.
First-in-class programs — novel cell therapies, gene editing treatments, iPSC-derived biologics, RNA-based individualized therapies — operate outside those assumptions at nearly every level. The population is small. The endpoints are being defined for the first time. The investigators are learning the procedure as they execute it. The specimen handling requirements are exacting, time-sensitive, and non-recoverable if missed.
Each of these characteristics creates a specific concentration of execution risk. Understanding where those concentrations are, and what platform design responds to each one, is the infrastructure selection question that first-in-class sponsors need to answer before the first site goes live — not after.
What Makes First-in-Class Risk Structurally Different
In a conventional Phase 3 program with 400 participants, the statistical architecture is designed to absorb a degree of operational noise. Power calculations account for dropout. Sensitivity analyses address missing data. A small number of eligibility adjudications or imputed assessments, handled transparently and consistently, rarely determine the outcome.
That tolerance is a function of n. When a program enrolls 20, 30, or 50 participants — as is common in Phase 1/2 programs for novel modalities — the statistical weight of each individual participant's data is fundamentally different. A single ineligible patient in a 40-patient trial carries more analytical consequence than five ineligible patients in a 400-patient trial. A missed primary endpoint assessment that requires imputation in a small-n study can shift the direction of the point estimate, not just its precision.
This is not a theoretical concern. It is a direct consequence of how statistical inference works under small sample conditions. The operational infrastructure running a first-in-class program needs to be calibrated to that reality — which means the tolerance for eligibility ambiguity, missed assessments, and data inconsistencies that might be acceptable in a conventional program is not available in a small-n first-in-class study.
The Novel Endpoint Problem
Conventional efficacy endpoints — HbA1c reduction, LVEF change, progression-free survival — have extensive operational precedent. The clinical research community understands how to capture them, what constitutes a valid assessment, how to handle edge cases, and what the audit trail for a disputed data point should look like.
Novel endpoints in first-in-class programs have none of that precedent. When a program is evaluating functional engraftment of an iPSC-derived cell therapy, or measuring a novel biomarker as a surrogate for a genetic correction, the protocol's endpoint definition is being operationalized for the first time. There is no institutional knowledge at the site level about what “correct” capture looks like. There is no community standard for handling the edge cases the protocol's authors didn't anticipate when they wrote the inclusion criteria.
This creates a protocol translation problem that is different in kind from the challenge of implementing a conventional endpoint. The question is not whether the system can execute a known procedure correctly. The question is whether the system's logic layer can enforce an endpoint definition that has never been operationalized before — and flag, in real time, when a data entry event doesn’t conform to that definition.
BDD-based protocol specifications address this directly. By translating the endpoint definition into plain-language, machine-executable specifications before the study goes live, ambiguity about what constitutes a valid assessment is resolved at configuration time rather than during data review. When a data entry event triggers a specification failure, the system flags it immediately — before the data enters the analysis dataset — rather than surfacing it during a monitoring visit or database lock query cycle.
Site Naivety and the Execution Gap
First-in-class programs routinely activate sites at academic medical centers and specialty centers that have never executed the relevant procedure at scale. An investigator who has performed a procedure in a research context, or observed it at another institution, is not the same as an investigator who has executed it across 15 participants with a validated protocol and a trained coordinator team.
Site naivety is not a training problem in the conventional sense. Training addresses knowledge gaps. The execution gap in a novel modality program is deeper: it is the gap between knowing what the protocol requires and having the operational fluency to execute it consistently under real study conditions, across a range of participant presentations, over an 18-month enrollment period.
Platform-level guardrails cannot replace investigator competence, but they can prevent the most consequential category of site naivety failure: the protocol deviation that occurs not because the site team didn’t know the rule, but because the system allowed a rule violation to proceed without detection.
Deterministic eligibility enforcement, real-time workflow triggers, and automated alerts when a required assessment window is approaching or has been missed — these are not substitutes for site training. They are the operational safety net that catches the execution failures that training alone cannot prevent, and that are most likely to occur when a site team is still developing procedural fluency early in a study.
In a small-n program, those early-enrollment deviations carry disproportionate weight. The first five participants enrolled often represent 10–25% of the total analysis population. The data quality of those early enrollments is not a warmup period — it is part of the primary dataset.
Logistics Orchestration in Novel Modality Programs
The specimen handling and logistics requirements of cell therapy and gene editing programs introduce an operational complexity category that does not exist in conventional small-molecule or biologic trials.
Autologous cell therapy programs require leukapheresis collections to be shipped to manufacturing facilities under controlled temperature and timing conditions, processed, manufactured into a patient-specific product, returned to the site, and administered within a defined window. Each step in that chain has timing requirements that are protocol-defined, non-negotiable, and non-recoverable if missed. A specimen that misses its processing window is not a query to be resolved — it is a patient who cannot receive their assigned treatment.
The operational infrastructure required to support this is not a monitoring function. It is an orchestration function. The platform needs to know, at the moment a leukapheresis collection event is recorded, that a logistics workflow must be triggered — a courier scheduled, a manufacturing notification issued, a return timeline established. That trigger needs to be automatic, not dependent on a coordinator remembering to initiate it, and it needs to be linked to the protocol’s timing requirements so that deviations from the expected timeline generate immediate alerts rather than retrospective discovery.
Event-driven architecture is the platform design pattern that enables this. When every protocol-relevant event is captured in real time and linked to the workflow dependencies it triggers, the logistics chain for a complex specimen handling procedure becomes a governed operational sequence rather than a manually coordinated series of tasks. The audit trail records not just that the collection occurred, but that the downstream logistics chain was initiated, that timing thresholds were met or missed, and what actions were taken at each step.
Infrastructure Selection Before First Patient In
The four risk concentrations described above — small-n statistical sensitivity, novel endpoint capture, site naivety, and logistics orchestration — all share a common characteristic: they are substantially harder to remediate after a study is live than to prevent through infrastructure design before it begins.
A protocol review conducted before system configuration — with the specific goal of evaluating whether the platform’s logic layer can enforce each risk-relevant requirement programmatically — surfaces the translation gaps that would otherwise appear as deviations during execution. Eligibility criteria that cannot be evaluated by the system without additional data elements. Endpoint definitions that require clarification before they can be rendered as executable specifications. Logistics triggers that depend on vendor integrations that haven’t been configured yet.
In a first-in-class program, those gaps are not minor configuration issues. They are structural vulnerabilities in the evidentiary record of a study whose entire scientific contribution may rest on 20 to 50 participants.
The infrastructure question for first-in-class sponsors is therefore not whether their platform can handle the study — most platforms can handle data entry. The question is whether the platform was designed to enforce protocol logic, orchestrate vendor workflows, and produce a real-time, immutable evidence trail for a study where the margin for operational error is essentially zero.
That question should be answered during protocol development. Not at site activation. Not during the first monitoring visit. Before any participant is enrolled.
Conclusion
First-in-class clinical programs represent the scientific frontier of drug development. They also represent an operational environment that is structurally more demanding than the model most clinical data infrastructure was built to serve — smaller populations, no precedent for endpoint capture, sites learning procedures in real time, and logistics requirements that are unforgiving of missed coordination.
The platform design principles that address this environment are not different in kind from best practice in conventional trial execution. Deterministic protocol logic, event-driven workflow orchestration, real-time audit trails, and upstream engagement before configuration begins are the same capabilities that improve execution quality in any clinical program.
What is different in a first-in-class program is the consequence of not having them. In a study where each participant represents a meaningful fraction of the total analysis population, and where the endpoints and procedures are being operationalized for the first time, infrastructure designed for data collection is not the same as infrastructure designed for protocol execution. The distinction is most visible when it is most consequential — which in a first-in-class program, is from the moment the first site goes live.
Alethium’s Clinical Data Platform is designed for complex, high-velocity trials across therapeutic areas including cell therapy, gene editing, and novel biologic programs. The platform’s BDD-based Automation Engine, event-driven architecture, and integrated CRO services are built to address the specific execution demands these programs create.
